10/532452 C120c'd PCT/PTO 22 APR 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

Based on PCT/JP2003/013528

Filed:

Intl. Filing 23 October 2003

1st Inventor:

Yukio SHIMOMURA

For:

Antibody and Utilization of the Same

Atty. Dkt. No.

3104 US0P

Art Unit:

tba

Examiner:

tba

Allowed:

Batch:

Paper No.:

Information Disclosure Statement

MAIL STOP PCT P.O. Box 1450 Commissioner for Patents Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Forms PTO/SB/08A and PTO/SB/08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached form PTO/SB/08A be returned in accordance with MPEP §609.

Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants'

attorney.

Dated:

(847) 383-3372

(847) 383-3391

Respectfully submitted

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA

JC12 Rec'd PCT/PTO 22 APR 2009

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449/PTO	Complete if Known			
		Application Number	Based on PCT/JP2003/013528		
IN	FORMATION DISCLOSURE	Filing Date	Intl. Filing 23 October 2003		
		First Named Inventor	Yukio SHIMOMURA		
S	TATEMENT BY APPLICANT	Art Unit	tba		
	(Use as many sheets as necessary)	Examiner Name	tba		
Sheet	1 of 3	Attorney Docket Number	3104 US0P		

U. S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant		
		Number-Kind Code ^{2 (# known)}			Figures Appear		
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-		(3)			
		US-					
		US-					
		US-					
•		US-					
		US-					
		US-					
		US-					
		US-	"				

		FOREIC	ON PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
	A1	EP 1241479 A2	09/18/2002	Immundiagnostik AG		
	A2	JP 2002-087982A-Abstract only	03/27/2002	Nippon Kayaku Co Ltd		
	A3	WO 01/37780 A2	05/31/2001	SmithKline Beeacham Corp.		
	A4	WO 01/04298 A1-Abstract only	01/18/2001	Takeda Chemical Industries		
	A5	WO 00/32627-Abstract only	06/08/2000	Takeda Chemical Industries		
	A6	WO 02/14513 A1 - Abstract only	02/21/2002	Takeda Chemical Industries		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

JC13 Rec'd PCT/PTO 22 APR 2005

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Dia collection of information unless it contains a valid OVA

Sub	estitute for form 1449/PTO	Complete if Known		
		Application Number	Based on PCT/JP2003/013528	
IN	FORMATION DISCLOSURE	Filing Date	Intl. Filing 23 October 2003	
		First Named Inventor	Yukio SHIMOMURA	
S	TATEMENT BY APPLICANT	Art Unit	tba	
(Use as many sheets as necessary)		Examiner Name	tba	
Sheet	2 of 3	Attorney Docket Number	3104 US0P	

			U. S. PATENT D		
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	ļ	Number-Kind Code ^{2 (# known)}			rigures Appear
		US-			
	ļ	US-			
		US-			-
•		US-		·	
	İ	US-			· · · · · · · · · · · · · · · · · · ·
		US-		······································	
		US-	1		
		US-			
	l	US-			

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
	A7	WO 03/064646 - Abstract only	08/07/2003	Takeda Chemical Industries		
-	ļ					
	ļ					L
	l]

Examiner	 Date	· · · · · · · · · · · · · · · · · · ·	_
Signature	Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For ²See Kinds Codes of Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	Substitute for form 1449/PTO			Complete if Known		
Casolina				Application Number	Based on PCT/JP2003/013528	
INF	ORMATION	DIS	CLOSURE	Filing Date	Intl. Filing 23 October 2003	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Yukio SHIMOMURA	
	(Use as many she	ete ae n	necessary)	Art Unit	tba	
	(See as many sne	013 03 7		Examiner Name	tba	
Sheet	3	of	3	Attorney Docket Number	3104 US0P	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A8	YUTA KOBAYASHI, et al., "Radioimmunoassays for Fish Tail Neuropeptides: II. Development of a Specific and Sensitive Assay for and the Occurrence of Immunoreactive Urotensin II in the Central Nervous System and Blood of Catostomus Commersoni", J. Pharm. Methods, (1986), pp. 321-333, Vol. 15, No. 4	
	A9	KYOKO OWADA, et al., "Urotensin II-immunoreactive Neurons in the Caudal Neurosecretory System of Freshwater and Seawater Fish", Cell and Tissue Research, (1985), pp. 349-354, Vol. 239, No. 2	
	A10	MASAAKI MORI, et al., "Urotensin II is the Endogenous Ligand of a G-Protein-Coupled Orphan Receptor, SENR (GPR14)", Biochemical and Biophysical Research Communications, (1999), pp. 123-129, Vol. 265, No. 1	
	A11	TSUKASA SUGO, et al., "Identification of Urotensin II-Related Peptide as the Urotensin II-Immunoreactive Molecule in the Rat Brain", Biochemical and Biophysical Research Communications, (2003), p. 860-868, Vol. 310, No. 3	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.